Phil Tennant

Phil is the newly appointed (May 2022) senior vice president and head of the U.S. oncology business unit at Astellas Pharma, providing executive leadership to a team of over 250 field and marketing staff to deliver the growth strategies for the company’s $3 billion+ oncology franchise.

Prior to this, Phil served for two-and-a-half years as SVP and head of the strategic brand marketing function at Astellas, where he led the global marketing team in the launches of Xospata and Padcev, the expansion of the market for Xtandi and the commercial launch strategy for the investigational monoclonal antibody Zolbetuximab in gastric cancer.

Before joining Astellas, Phil’s 30-year career saw him work for several notable pharmaceutical companies in multiple geographies in sales and marketing roles of progressive responsibility: Merck, Sharp & Dohme in the UK; AstraZeneca in UK, Japan, Europe and Australia; and then Bristol-Myers Squibb in Australia and the U.S., where his last role was heading up the $2 billion dollar U.S. hematology marketing franchise.

Phil has relished the opportunity to have leadership impact in global, regional and country/P&L roles across several therapeutic areas, particularly through the recent revolution in oncology therapeutics, which has been his area of focus for the past 11 years.